The study will proceed successively from Group A to Group E with a 4-week interval between Groups. The Safety Monitoring Board (SMB) will be convened at the end of the 4-week interval and review all available safety data. Based on the safety outcomes from the 3 subjects in each Group, the SMB will recommend, according to a predetermined rule, whether to enroll 3 new subjects into the next Group, to continue to collect additional information from the same Group, to enroll additional subjects into the same Group, or to suspend the study. Potential subjects will be recruited for the study but put on a waiting list until SMB approval of their treatment. The SMB will consist of 3 neurologists with expertise in ALS, 1 spinal neurosurgeon, 1 neurooncologist, 1 transplant immunologist, and the scientific director of the ALS Association.